logo
Plus   Neg
Share
Email

Sanofi Q1 Profit Rises; Backs 2019 Business EPS Outlook - Quick Facts

French drug giant Sanofi SA (SNYNF,SNY) reported Friday that its net income attributable to equity holders for the first quarter of 2019 rose to 1.14 billion euros from last year's 1.02 billion euros, with earnings per share rising to 0.91 euros from 0.81 euros in the prior year.

Net income, excluding the held for exchange Animal Health business, increased to 1.15 billion euros from 1.05 billion euros in the prior year. Earnings per share, excluding the held for exchange AnimalHealth business, were 0.91 euros, up from 0.81 euros in the previous year.

First-quarter business net income increased 10.5 percent to 1.77 billion euros, and increased 9 percent at CER. Business earnings per share rose 10.9 percent to 1.42 euros on a reported basis, and increased 9.4 percent at CER.

Quarterly sales increased 6.2 percent to 8.39 billion euros from 7.90 billion euros in the year-ago quarter. At CER, company sales grew 4.2 percent.

Exchange rate movements had a positive effect of 2.0 percentage points mainly driven by the U.S. dollar, which largely offset the negative impact from the Argentine Peso, Turkish Lira, Brazilian Real and Russian Ruble.

Looking ahead to fiscal 2019, Sanofi said it continues to expect business earnings per share to grow between 3 percent and 5 percent at CER, barring unforeseen major adverse events. Applying the average April 2019 exchange rates, the company estimates the currency impact on 2019 business earnings per share to be around 2 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Aeronautics and Space Administration or NASA extended its contract with Boeing to build the rocket core stages for its Space Launch System or SLS beyond the first two Artemis missions, and through the next decade. Boeing is the current lead contractor for the core stages of the rockets for the first two missions. The new contract includes the production of ten SLS core stages. The U.S. Food and Drug Administration approved an all-time record total of 1,171 generic drugs in fiscal 2019, breaking its previous record of 971 approvals in fiscal 2018. This year's approvals include 935 full approvals and 236 tentative approvals. A generic drug is a pharmaceutical drug that contains the same chemical substance and performs the same functions as a branded drug. Air Canada has extended its grounding of Boeing's 737 MAX-8 aircraft and removed it from its flying schedule until February 14, 2020. The airline had earlier said its fleet of 24 grounded jetliners will not join its schedules until January 8, 2020. The Canadian flag carrier said the extension is a result of the ongoing regulatory uncertainty about the timing of the aircraft returning to service.
Follow RTT
>